7 Optimising Prevention of Pneumococcal Disease with Pneumococcal Conjugate Vaccines Pfizer Symposium, 23 October 2010, 13:00-14:00
نویسندگان
چکیده
منابع مشابه
Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines.
Streptococcus pneumoniae is one of the leading causes of both invasive and noninvasive diseases in the pediatric population and continues to represent a significant public health burden worldwide. The increasing incidence of antibioticresistant strains of the pathogen has complicated treatment and management of the various pneumococcal disease manifestations. Thus, the best management strategy ...
متن کاملPneumococcal conjugate vaccines
To assess whether certain serogroups of Streptococcus pneumoniae are preferentially associated with specific disease manifestations, we analyzed all recent pneumococcal disease studies and assessed the relative frequency of isolation of each serogroup by clinical site (as a proxy for different disease states). In all age groups, serogroups 1 and 14 were more often isolated from blood, and serog...
متن کاملNasopharyngeal Pneumococcal Colonization among Children after Pneumococcal Conjugate Vaccine Introduction
World Health Organization has recommended all countries to introduction of Pneumococcal Conjugate Vaccine (PCV) in routine immunization schedule, especially those countries with higher rate of mortality in children. However, Islamic Republic of Iran and more than 50 other countries including Algeria, Antigua and Barbuda, Belarus, Belize, Bhutan, Bosnia and Herzegovina, Brunei Darussalam, Cabo V...
متن کاملVaccines for the Prevention of Pneumococcal Disease.
I caused by Streptococcus p n e u m o n i a e r e m a i n a m a j o r public health problem worldwide. Due to large serotype diversity i n p n e u m o c o c c u s , v a c c i n e s that induce antibody responses against multiple capsular antigens h a ve b e e n d e ve l o p e d . At t h e moment, there are two licensed anti-pneumococcal vaccines for possible use in elderly people: the classical...
متن کاملThe future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children.
Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In June 2000, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommended the universal administration of pneumococcal conjugate vaccine for all children 23 months of age and younger and for children 24 to 59 months of age who are at high risk for serious pneumococcal diseas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Research
سال: 2010
ISSN: 0031-3998,1530-0447
DOI: 10.1203/00006450-201011001-00007